You are here

  • Home
  • Archive
  • Volume 3, Issue 1
  • No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysis

Article info

Article menu

Download PDFPDF

Rheumatoid arthritis
Original article
No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysis

Authors

  • Claire Baradat Rheumatology Center, Purpan Teaching Hospital, CHU of Toulouse, Toulouse, France Paul Sabatier University, Toulouse, France PubMed articlesGoogle scholar articles
  • Yannick Degboé Rheumatology Center, Purpan Teaching Hospital, CHU of Toulouse, Toulouse, France Paul Sabatier University, Toulouse, France Inserm, UMR 1043, Toulouse, France PubMed articlesGoogle scholar articles
  • Arnaud Constantin Rheumatology Center, Purpan Teaching Hospital, CHU of Toulouse, Toulouse, France Paul Sabatier University, Toulouse, France Inserm, UMR 1043, Toulouse, France PubMed articlesGoogle scholar articles
  • Alain Cantagrel Rheumatology Center, Purpan Teaching Hospital, CHU of Toulouse, Toulouse, France Paul Sabatier University, Toulouse, France Inserm, UMR 1043, Toulouse, France PubMed articlesGoogle scholar articles
  • Adeline Ruyssen-Witrand Rheumatology Center, Purpan Teaching Hospital, CHU of Toulouse, Toulouse, France Paul Sabatier University, Toulouse, France Inserm, UMR 1027, Toulouse, France PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Adeline Ruyssen-Witrand; ruyssen-witrand.a{at}chu-toulouse.fr
View Full Text

Citation

Baradat C, Degboé Y, Constantin A, et al
No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysis
RMD Open 2017;3:e000352. doi: 10.1136/rmdopen-2016-000352

Publication history

  • Received August 24, 2016
  • Revision received November 2, 2016
  • Accepted November 7, 2016
  • First published February 23, 2017.
Online issue publication 
July 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/